{
  "slug": "calcium-akg",
  "name": "Calcium Alpha-Ketoglutarate (CaAKG)",
  "alternate_names": [
    "CaAKG",
    "Calcium AKG",
    "Calcium Alpha-Ketoglutarate",
    "Ca-AKG"
  ],
  "mechanism": [
    "TCA-cycle intermediate / metabolic flux substrate (research-context)",
    "Co-factor for 2-oxoglutarate-dependent dioxygenases incl. TET demethylases (epigenetic-regulation mechanism · preclinical)",
    "AMPK pathway modulation (mechanistic)",
    "OXGR1 receptor signaling (mechanistic)",
    "Calcium-salt delivery vehicle"
  ],
  "target": [
    "TCA cycle / mitochondrial metabolism",
    "DNA-methylation / epigenetic-age markers (research endpoint)",
    "Calcium-phosphate balance (dialysis disease context)"
  ],
  "use_case": [
    "healthy-aging biomarker research (epigenetic-age · open-label/protocol evidence only)",
    "metabolic / TCA-flux research context",
    "calcium-phosphate balance in dialysis (disease-population trial · not a supplement claim)"
  ],
  "body_system": [
    "MITO",
    "CELL",
    "EPIGEN",
    "MUSCULO"
  ],
  "evidence_tier": "C",
  "evidence_anchor_pmid_count": 0,
  "dosage_range": "Research-context reference: 1000 mg/day CaAKG was the dose used in the Rejuvant open-label epigenetic-age study (Demidenko 2021); no established RDA or efficacy-validated dose. Educational reference only.",
  "safety_notes": "Long-term tolerability data come largely from dialysis/ICU populations (OKG and CaAKG) with no serious adverse events reported; FDA GRAS self-affirmation pathway. No adequate data in pregnancy/lactation. CaAKG delivers supplemental calcium — total calcium intake should be considered. Long-term safety in healthy aging populations beyond the short open-label/trial durations is not established. Educational information only; not medical advice.",
  "regulatory": {
    "fda": "GRAS self-affirmation pathway; marketed as a dietary supplement under DSHEA (Rejuvant and other brands legally sold). No specific FDA-authorized health claim.",
    "efsa": "Novel Food / EU status: 0 EFSA-authorised and 0 non-authorised health claims (Reg 1924/2006). Some member states permit CaAKG as a food supplement; no EU-level authorized claim.",
    "anvisa": "No specific ANVISA approval; would require case-by-case evaluation under the dietary-supplement framework (RDC 243/2018). No IN 28/2018 Anexo V alegação funcional for CaAKG."
  },
  "authorized_claims": [],
  "ingredient_hub_url": "https://asxan.ai/ingredients/calcium-akg/",
  "related_goal_slugs": [
    "longevity-stack"
  ],
  "related_lifestyle_slugs": [
    "senior-60-plus"
  ],
  "last_evidence_review": "2026-06-13",
  "schema_version": "nc-public-v0.2",
  "api_version": "nc-public-v0.3",
  "_meta": {
    "last_evidence_review": "2026-06-13",
    "ip_axes_disclosed": {
      "public_axes": [
        "mechanism",
        "target",
        "use_case",
        "body_system",
        "evidence_tier",
        "dosage_range",
        "safety_notes",
        "regulatory",
        "authorized_claims"
      ],
      "ip_axes_not_exposed": [
        "proprietary_formula_ratios",
        "clinical_protocol_internals",
        "rnd_pipeline_compounds",
        "supplier_specific_grade_specifications",
        "unpublished_endpoint_data"
      ],
      "rationale": "asxan.ai surfaces the educational, evidence-tier-disclosed slice. Formula composition, clinical-protocol internals, and RnD pipeline data are intentionally outside this public surface."
    }
  }
}